Glaxo (GSK) Q4 Earnings Lag Estimates, Shingrix Back on Track

GlaxoSmithKline plc GSK reported fourth-quarter 2020 adjusted earnings of 62 cents per American depositary share (“ADS”), which missed the Zacks Consensus Estimate of 70 cents. Moreover, adjusted earnings were down 6% year over year on a reported basis and 5% at constant exchange rate (“CER”) due to higher research and development expenses.